|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Hugo Brugiere||Chairman, GM & CEO||85k||S.O.||S.O.|
|Prof. Daniel Zagury||Founder, Chairman of Scientific Research Committee & Director||6k||S.O.||S.O.|
|Mr. Vincent Serra||Scientific & Operational Director||188,8k||S.O.||1970|
|Mr. Alexandre Courtoux||Admin. & Financial Director||S.O.||S.O.||S.O.|
|Charlene Masson||Corp. Communication & Investor Relations||S.O.||S.O.||S.O.|
|Ms. Valerie Salentey Ph.D.||Head of Regulatory Affairs||S.O.||S.O.||S.O.|
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
L’ISS Governance QualityScore de Neovacs S.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..